IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

June 25, 2026

IceCure Medical Ltd. has announced that it has regained compliance with the minimum bid price requirement set by Nasdaq. The company received written notice from Nasdaq Stock Market LLC on June 18, 2026, confirming that its ordinary shares maintained a closing bid price of $1.00 or greater for 10 consecutive business days, from June 4 to June 17, 2026.

This determination concludes the bid price deficiency matter, as the company is now in compliance with Nasdaq Listing Rule 5550(a)(2), which mandates that listed securities maintain a minimum bid price of $1.00 per share.

IceCure Medical specializes in developing and marketing liquid-nitrogen-based cryoablation systems aimed at the destruction of tumors through freezing. The company's technology is tailored for various cancers, including breast, kidney, bone, and lung cancers, offering a minimally invasive alternative to surgical tumor removal. Its flagship device, ProSense®, is currently marketed globally and has received various regulatory approvals.

The company's CFO, Meir Peleg, is available for media inquiries via email at [email protected] or by phone at +1-888-902-5716.

For more information, the company's logo can be accessed at the following link: https://mma..com/media/2319310/IceCure_Medical_Logo.jpg.

Disclaimer: This press release has been distributed on behalf of the issuing organization. PR Gun acts solely as a distribution platform and has not independently verified the accuracy, completeness, or validity of the statements contained herein.